

CORRECTION

Open Access



Correction: Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy

The AIMM Trial Group; Alaa Abouhajar¹, Lisa Alcock², Theophile Bigirumurame³, Penny Bradley⁴, Laura Brown⁵, Ian Campbell⁴, Silvia Del Din², Julie Faitg⁵, Gavin Falkous⁵, Grainne S. Gorman^{5,6}, Rachel Lakey¹, Robert McFarland^{5,6}, Jane Newman⁵, Lynn Rochester², Vicky Ryan³, Hesther Smith⁴, Alison Steel¹, Renae J. Stefanetti⁵, Huizhong Su⁵, Robert W. Taylor^{5,6}, Naomi J. P. Thomas^{5,6*}, Helen Tuppen⁵, Amy E. Vincent⁵, Charlotte Warren⁵ and Gillian Watson¹

Correction: *Trials* 23, 789 (2022)

<https://doi.org/10.1186/s13063-022-06544-x>

Following the publication of the original article [1], we were notified that the name of the 7th author has been incorrectly spelled.

Originally published name: Sylvia Del Din

Corrected name: Silvia Del Din

The original article has been corrected.

Newcastle University, Newcastle upon Tyne NE4 5PL, UK. ³Population Health Sciences Institute, Newcastle University, Ridley 1 Building, Newcastle upon Tyne NE1 7RU, UK. ⁴Pharmacy Directorate, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Freeman Road, Newcastle Upon Tyne NE7 7DN, UK. ⁵Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne NE2 4HH, UK. ⁶NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne NE1 4LP, UK.

Published online: 05 October 2022

Author details

¹Newcastle Clinical Trials Unit, 1-4 Claremont Terrace, Newcastle University, Newcastle upon Tyne NE2 4AE, UK. ²Brain and Movement Research Group, Clinical Ageing Research Unit, Translational and Clinical Research Institute,

The original article can be found online at <https://doi.org/10.1186/s13063-022-06544-x>.

*Correspondence: naomi.thomas@newcastle.ac.uk

⁶NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne NE1 4LP, UK

Full list of author information is available at the end of the article

Reference

1. The AIMM Trial Group. Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy. *Trials*. 2022;23:789. <https://doi.org/10.1186/s13063-022-06544-x>.



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.